{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:00:36Z","timestamp":1790150436419,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"DOI":"10.1038\/s41417-026-01083-y","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:08:37Z","timestamp":1790100517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["POLE2 of tumor cells promotes OPN secretion based on PCLAF to drive M2 macrophage polarization in clear cell renal cell carcinoma"],"prefix":"10.1038","author":[{"given":"An-rui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-hang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-jian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-sheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-juan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3326-2290","authenticated-orcid":false,"given":"Qi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7526-4813","authenticated-orcid":false,"given":"Li-chen","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"1083_CR1","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s42003-024-06478-x","volume":"7","author":"J Zvirblyte","year":"2024","unstructured":"Zvirblyte J, Nainys J, Juzenas S, Goda K, Kubiliute R, Dasevicius D, et al. Single-cell transcriptional profiling of clear cell renal cell carcinoma reveals a tumor-associated endothelial tip cell phenotype. Commun Biol. 2024;7:780.","journal-title":"Commun Biol"},{"key":"1083_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116805","volume":"175","author":"A Kowalewski","year":"2024","unstructured":"Kowalewski A, Borowczak J, Maniewski M, Gostomczyk K, Grzanka D, Szylberg L. Targeting apoptosis in clear cell renal cell carcinoma. Biomed Pharmacother. 2024;175. 116805.","journal-title":"Biomed Pharmacother"},{"key":"1083_CR3","doi-asserted-by":"crossref","unstructured":"Zhang J, Zhang Q. VHL and hypoxia signaling: beyond HIF in cancer. Biomedicines. 2018;6(1):35.","DOI":"10.3390\/biomedicines6010035"},{"key":"1083_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/onc.2015.113","volume":"35","author":"\u00c1 Ord\u00f3\u00f1ez-Navadijo","year":"2016","unstructured":"Ord\u00f3\u00f1ez-Navadijo \u00c1, Fuertes-Yebra E, Acosta-Iborra B, Balsa E, Elorza A, Aragon\u00e9s J, et al. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1\u03b1 from SART1-mediated degradation in clear-cell renal cell carcinoma. Oncogene. 2016;35:587\u201394.","journal-title":"Oncogene"},{"key":"1083_CR5","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.18632\/oncotarget.561","volume":"3","author":"C Sourbier","year":"2012","unstructured":"Sourbier C, Srivastava G, Ghosh MC, Ghosh S, Yang Y, Gupta G, et al. Targeting HIF2\u03b1 translation with Tempol in VHL-deficient clear cell renal cell carcinoma. Oncotarget. 2012;3:1472\u201382.","journal-title":"Oncotarget"},{"key":"1083_CR6","doi-asserted-by":"crossref","unstructured":"Teisseire M, Giuliano S, Pag\u00e8s G. Combination of anti-angiogenics and immunotherapies in renal cell carcinoma show their limits: targeting fibrosis to break through the glass ceiling? Biomedicines. 2024;12:385","DOI":"10.3390\/biomedicines12020385"},{"key":"1083_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","volume":"40","author":"R Sharma","year":"2021","unstructured":"Sharma R, Kadife E, Myers M, Kannourakis G, Prithviraj P, Ahmed N. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. J Exp Clin Cancer Res. 2021;40:186.","journal-title":"J Exp Clin Cancer Res"},{"key":"1083_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/iju.15042","volume":"29","author":"Y Sekino","year":"2022","unstructured":"Sekino Y, Teishima J, Liang G, Hinata N. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. Int J Urol. 2022;29:1419\u201328.","journal-title":"Int J Urol"},{"key":"1083_CR9","doi-asserted-by":"crossref","unstructured":"Abah MO, Ogenyi DO, Zhilenkova AV, Essogmo FE, Ngaha Tchawe YS, Uchendu IK, et al. Innovative therapies targeting drug-resistant biomarkers in metastatic clear cell renal cell carcinoma (ccRCC). Int J Mol Sci. 2024;26, 265","DOI":"10.3390\/ijms26010265"},{"key":"1083_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1114461","volume":"13","author":"M Yu","year":"2023","unstructured":"Yu M, Qian K, Wang G, Xiao Y, Zhu Y, Ju L. Histone methyltransferase SETD2: an epigenetic driver in clear cell renal cell carcinoma. Front Oncol. 2023;13:1114461.","journal-title":"Front Oncol"},{"key":"1083_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF00048092","volume":"4","author":"LA Zwelling","year":"1985","unstructured":"Zwelling LA. DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Metastasis Rev. 1985;4:263\u201376.","journal-title":"Cancer Metastasis Rev"},{"key":"1083_CR12","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1091\/mbc.e12-05-0339","volume":"23","author":"T Handa","year":"2012","unstructured":"Handa T, Kanke M, Takahashi TS, Nakagawa T, Masukata H. DNA polymerization-independent functions of DNA polymerase epsilon in assembly and progression of the replisome in fission yeast. Mol Biol Cell. 2012;23:3240\u201353.","journal-title":"Mol Biol Cell"},{"key":"1083_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34911-4","volume":"13","author":"S Vipat","year":"2022","unstructured":"Vipat S, Gupta D, Jonchhe S, Anderspuk H, Rothenberg E, Moiseeva TN. The non-catalytic role of DNA polymerase epsilon in replication initiation in human cells. Nat Commun. 2022;13:7099.","journal-title":"Nat Commun"},{"key":"1083_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01477-4","volume":"20","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Chen G, Song Y, Chen Z, Chen X. POLE2 knockdown reduce tumorigenesis in esophageal squamous cells. Cancer Cell Int. 2020;20:388.","journal-title":"Cancer Cell Int"},{"key":"1083_CR15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.cmet.2023.06.003","volume":"35","author":"W Zou","year":"2023","unstructured":"Zou W, Green DR. Beggars banquet: metabolism in the tumor immune microenvironment and cancer therapy. Cell Metab. 2023;35:1101\u201313.","journal-title":"Cell Metab"},{"key":"1083_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e30807","volume":"10","author":"Q Zuo","year":"2024","unstructured":"Zuo Q, Wu Y, Hu Y, Shao C, Liang Y, Chen L, et al. Targeting lipid reprogramming in the tumor microenvironment by traditional Chinese medicines as a potential cancer treatment. Heliyon. 2024;10:e30807.","journal-title":"Heliyon"},{"key":"1083_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.7150\/jca.49692","volume":"12","author":"S Zhu","year":"2021","unstructured":"Zhu S, Luo Z, Li X, Han X, Shi S, Zhang T. Tumor-associated macrophages: role in tumorigenesis and immunotherapy implications. J Cancer. 2021;12:54\u201364.","journal-title":"J Cancer"},{"key":"1083_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00281-023-00988-2","volume":"45","author":"P Sadhukhan","year":"2023","unstructured":"Sadhukhan P, Seiwert TY. The role of macrophages in the tumor microenvironment and tumor metabolism. Semin Immunopathol. 2023;45:187\u2013201.","journal-title":"Semin Immunopathol"},{"key":"1083_CR19","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.7150\/thno.50928","volume":"11","author":"S Han","year":"2021","unstructured":"Han S, Wang W, Wang S, Yang T, Zhang G, Wang D, et al. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes. Theranostics. 2021;11:2892\u2013916.","journal-title":"Theranostics"},{"key":"1083_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18246-0","volume":"12","author":"T Zou","year":"2022","unstructured":"Zou T, Gao S, Yu Z, Zhang F, Yao L, Xu M, et al. Salvianolic acid B inhibits RAW264.7 cell polarization towards the M1 phenotype by inhibiting NF-\u03baB and Akt\/mTOR pathway activation. Sci Rep. 2022;12:13857.","journal-title":"Sci Rep"},{"key":"1083_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108139","volume":"100","author":"XL Wang","year":"2021","unstructured":"Wang XL, Chen F, Shi H, Zhang M, Yan L, Pei XY, et al. Oxymatrine inhibits neuroinflammation byRegulating M1\/M2 polarization in N9 microglia through the TLR4\/NF-\u03baB pathway. Int Immunopharmacol. 2021;100:108139.","journal-title":"Int Immunopharmacol"},{"key":"1083_CR22","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1007\/s00262-023-03573-6","volume":"72","author":"ES Zwart","year":"2023","unstructured":"Zwart ES, van Ee T, Affandi AJ, Boyd LNC, Rodriguez E, den Haan JMM, et al. Spatial immune composition of tumor microenvironment in patients with pancreatic cancer. Cancer Immunol Immunother. 2023;72:4385\u201397.","journal-title":"Cancer Immunol Immunother"},{"key":"1083_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12931-024-02772-8","volume":"25","author":"Y Zuo","year":"2024","unstructured":"Zuo Y, Li B, Gao M, Xiong R, He R, Li N, et al. Novel insights and new therapeutic potentials for macrophages in pulmonary hypertension. Respir Res. 2024;25:147.","journal-title":"Respir Res"},{"key":"1083_CR24","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3389\/fimmu.2019.01643","volume":"10","author":"Z Zong","year":"2019","unstructured":"Zong Z, Zou J, Mao R, Ma C, Li N, Wang J, et al. M1 macrophages induce PD-L1 expression in hepatocellular carcinoma cells through IL-1\u03b2 signaling. Front Immunol. 2019;10:1643.","journal-title":"Front Immunol"},{"key":"1083_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jare.2024.06.014","volume":"71","author":"H Zhong","year":"2025","unstructured":"Zhong H, Zhou S, Yin S, Qiu Y, Liu B, Yu H. Tumor microenvironment as niche constructed by cancer stem cells: breaking the ecosystem to combat cancer. J Adv Res. 2025;71:279\u201396.","journal-title":"J Adv Res"},{"key":"1083_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04575-9","volume":"21","author":"YR Li","year":"2023","unstructured":"Li YR, Fang Y, Lyu Z, Zhu Y, Yang L. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. J Transl Med. 2023;21:686.","journal-title":"J Transl Med"},{"key":"1083_CR27","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1200\/JCO.19.00075","volume":"37","author":"WZ Zhong","year":"2019","unstructured":"Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J Clin Oncol. 2019;37:2235\u201345.","journal-title":"J Clin Oncol"},{"key":"1083_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1505509","volume":"16","author":"L Zhao","year":"2025","unstructured":"Zhao L, Tan J, Su Q, Kuang Y. Integration of histopathological images and immunological analysis to predict M2 macrophage infiltration and prognosis in patients with serous ovarian cancer. Front Immunol. 2025;16:1505509.","journal-title":"Front Immunol"},{"key":"1083_CR29","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.2147\/IJN.S455021","volume":"19","author":"M Zhang","year":"2024","unstructured":"Zhang M, Yuan Q, Wang P, Zhang F, Wu D, Bai H, et al. Bone marrow mesenchymal stem cell-derived nanovesicles containing H8 improve hepatic glucose and lipid metabolism and exert ameliorative effects in type 2 diabetes. Int J Nanomedicine. 2024;19:6643\u201358.","journal-title":"Int J Nanomedicine"},{"key":"1083_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1371584","volume":"15","author":"Y Yin","year":"2024","unstructured":"Yin Y, Yang X, Cheng Z, Wang H, Lei J, Wang D, et al. Identification of extracellular matrix-related biomarkers in colon adenocarcinoma by bioinformatics and experimental validation. Front Immunol. 2024;15:1371584.","journal-title":"Front Immunol"},{"key":"1083_CR31","doi-asserted-by":"crossref","unstructured":"Ma S, Qin J, Zhang Y, Luan J, Sun N, Hou G, et al. Disrupting mitochondrial dynamics attenuates ferroptosis and chemotoxicity via upregulating NRF2-mediated FSP1 expression. Cell Rep. 2025;44:116234","DOI":"10.1016\/j.celrep.2025.116234"},{"key":"1083_CR32","doi-asserted-by":"crossref","unstructured":"Yuan Q, Gu J, Zhang J, Liu S, Wang Q, Tian T, et al. MyD88 in myofibroblasts enhances colitis-associated tumorigenesis via promoting macrophage M2 polarization. Cell Rep. 2021;34:108724","DOI":"10.1016\/j.celrep.2021.108724"},{"key":"1083_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ijc.29396","volume":"137","author":"I Spier","year":"2015","unstructured":"Spier I, Holzapfel S, Altm\u00fcller J, Zhao B, Horpaopan S, Vogt S, et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer. 2015;137:320\u201331.","journal-title":"Int J Cancer"},{"key":"1083_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s11658-023-00491-4","volume":"28","author":"W Zuo","year":"2023","unstructured":"Zuo W, Sun R, Ji Z, Ma G. Macrophage-driven cardiac inflammation and healing: insights from homeostasis and myocardial infarction. Cell Mol Biol Lett. 2023;28:81.","journal-title":"Cell Mol Biol Lett"},{"key":"1083_CR35","doi-asserted-by":"crossref","unstructured":"Zuo Y, Li Q, Xiong Q, Li J, Tang C, Zhang Y, et al. Naringin release from a nano-hydroxyapatite\/collagen scaffold promotes osteogenesis and bone tissue reconstruction. Polymers. 2022;14:3260.","DOI":"10.3390\/polym14163260"},{"key":"1083_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.actbio.2022.12.004","volume":"157","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Ma M, Han X, Li X, Huang J, Zhao Y, et al. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma. Acta Biomater. 2023;157:337\u201351.","journal-title":"Acta Biomater"},{"key":"1083_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.7150\/thno.45348","volume":"11","author":"D Kim","year":"2021","unstructured":"Kim D, Lee JH, Moon H, Seo M, Han H, Yoo H, et al. Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization (TACE) formulation on rabbit VX2 liver cancer model. Theranostics. 2021;11:79\u201392.","journal-title":"Theranostics"},{"key":"1083_CR38","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/s41556-022-00942-8","volume":"24","author":"L Zhu","year":"2022","unstructured":"Zhu L, Zhou X, Gu M, Kim J, Li Y, Ko CJ, et al. Dapl1 controls NFATc2 activation to regulate CD8(+) T cell exhaustion and responses in chronic infection and cancer. Nat Cell Biol. 2022;24:1165\u201376.","journal-title":"Nat Cell Biol"},{"key":"1083_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2023.100193","volume":"103","author":"W Zhao","year":"2023","unstructured":"Zhao W, Zhao J, Li K, Hu Y, Yang D, Tan B, et al. Oncogenic role of the NFATC2\/NEDD4\/FBP1 axis in cholangiocarcinoma. Lab Invest. 2023;103:100193.","journal-title":"Lab Invest"},{"key":"1083_CR40","doi-asserted-by":"crossref","unstructured":"Yin X, Wang L, Sun Y, Li S, Yu W, Wang S, et al. Identification of cell subpopulation-specific driver genes reveals ideal candidates for renal cell carcinoma immunotherapy. Int J Mol Sci. 2026;27:3467.","DOI":"10.3390\/ijms27083467"},{"key":"1083_CR41","doi-asserted-by":"crossref","unstructured":"Su X, Tan Q, Zheng L, Ding Z. Regulatory T cell dysfunction and exhaustion in uveitis: immunometabol ic mechanisms, microenvironmental drivers, and emerging therapeutic strategies. Front Immunol. 2026;17:1793865.","DOI":"10.3389\/fimmu.2026.1793865"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01083-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:04:58Z","timestamp":1790147098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01083-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":41,"alternative-id":["1083"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01083-y","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments, conducted between August 30, 2024, and September 30, 2024, were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of Mudanjiang Medical University (Approval No. IACUC20240830-256). The study involving human participants was reviewed and approved by the Ethics Committee of Harbin Medical University Cancer Hospital (Approval No. KY2023-34) and was conducted from April 6, 2023, to April 6, 2024, in accordance with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}